Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

Eitemau Tebyg

• Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
  gan: Burgaz, Sonia, et al.
  Cyhoeddwyd: (2019)
• Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
  gan: García, Concepción, et al.
  Cyhoeddwyd: (2018)
• Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
  gan: Aguareles, José, et al.
  Cyhoeddwyd: (2019)
• VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
  gan: Díaz-Alonso, Javier, et al.
  Cyhoeddwyd: (2016)
• Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
  gan: Burgaz, Sonia, et al.
  Cyhoeddwyd: (2021)